Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.43 |
| ▸ | NPC1 | O15118 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.43 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24038939 | 0.91 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL30517452 | 0.91 | RAB9A (0.43) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL30517443 | 0.88 | NPC1 (0.47) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL24039012 | 0.88 | NPC1 (0.47) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL30517474 | 0.86 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL24038649 | 0.86 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL24038648 | 0.85 | NPC1 (0.49) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL30517439 | 0.85 | NPC1 (0.49) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL25525687 | 0.84 | NPC1 (0.43) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL25213711 | 0.84 | RAB9A (0.46) | RAB9ANPC1SMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159513-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | RAB9A 2738/4885NPC1 3706/4885SMN1; SMN2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.